Special Issue

Immune-Related Adverse Events Diagnosis and Immunotherapy in Cancer

Message from the Guest Editors

Immunotherapy as a cancer treatment has represented a paradigm shift for patients suffering from many types of malignancies. Some patients experience incredible responses to these treatments, even in advanced cancer diseases, but others suffer from unexpected autoimmune aggressions triggered by immunotherapy. These are called immune-related adverse events, being sometimes life-threatening and still representing challenging situations which require a multidisciplinary approach. It is clear that further clinical and translational research is warranted. Prevention of immune-related adverse events, its diagnosis and treatment, and even more importantly, implications in the treatment of patients with cancer when adverse events occur are still issues that need to be clarified and approached by the scientific community. The main aim of this Special Issue, titled "Immune-Related Adverse Events Diagnosis and Immunotherapy in Cancer", is to provide useful and interesting knowledge to physicians who take care of cancer patients regarding immunotherapy treatment and its yet poorly known adverse events.

Guest Editors

Dr. Xavier Bosch

Head of Quick Diagnosis Unit, Department of Internal Medicine, Hospital Clínic, University of Barcelona School of Medicine, Villarroel 170, 08036 Barcelona, Spain

Dr. Javier Marco-Hernández

Department of Internal Medicine, Supportive and Palliative Care Unit in Cancer, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain

Deadline for manuscript submissions

closed (30 June 2022)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/91446

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

